Monthly Archives:

Radical Prostatectomy versus EBRT: An Analysis of Outcomes and Costs

Washington, DC—Researchers led by Nawar Hanna, MD, recently conduced an analysis to compare the implications of primary external bean radiation therapy (EBRT) or radical prostatectomy on urinary and gastrointestinal toxicities, use of androgen deprivation therapy (ADT), morbidity, mortality, and costs in patients with locally advanced (cT3) prostate cancer. Dr. Hanna reported results of the analysis during a poster session at ... Read More »

Active Surveillance versus EBRT and Health-Related Quality of Life in Low-Risk Prostate Cancer Patients

Washington, DC—The oncologic outcomes for patients receiving a diagnosis of low-risk prostate cancer are good. There are several possible treatment modalities for these patients, including those with curative intent such as external beam radiotherapy (EBRT), or active surveillance. Health-related quality of life issues are key in the decision-making process in selecting among the treatment options. John Banerji, MD, MCh (Urolog) ... Read More »

Treatment Patterns for Men with Very High-Risk Disease

Washington, DC—Very high-risk locally advanced prostate cancer has been a classification distinct from high-risk disease since 2014. When the National Comprehensive Cancer Network defined very high-risk disease as cT3b-T14, or primary Gleason pattern 5, or more than four biopsy cores with Gleason score 8-10, or multiple high-risk features. Jeffrey Tosoian, MD, MPH, presented a description of treatment patterns and short-term ... Read More »

Fluctuations in Age-Specific Median PSA and Risk of Prostate Cancer

Washington, DC—It has been shown in previous studies that men who present with prostate-specific antigen (PSA) levels above the age-specific median have a significantly increased risk of developing prostate cancer. However, according to researchers, there are few data on the change in the risk of prostate cancer with fluctuation in PSA over subsequent decades. Charles Nottingham, MD, MS, and colleagues ... Read More »

Perioperative Blood Transfusion Associated with Poorer 30-Day Outcomes in Prostatectomy

Washington, DC—For patients with clinically significant localized prostate cancer, radical prostatectomy remains a key element in treatment. Results of previous studies suggest that perioperative blood transfusion in surgeries for colon, pancreatic, esophageal, and gynecologic malignances may be associated with poorer long-term outcomes of recurrence, progression, and survival. Previous studies of the use of perioperative blood transfusion for prostatectomy have not ... Read More »

Update of IMAAGEN Trial Secondary End Points Results

Washington, DC—Daily abiraterone acetate at a dose of 1000 mg in combination with 10 mg of prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The IMAAGEN trial was designed to determine the ability of abiraterone acetate plus 5 mg of prednisone to decrease levels of prostate-specific antigen (PSA) in patients with non-metastatic CRPC (nmCRPC) ... Read More »